Drug And Gene Delivery Devices Market Report

Drug And Gene Delivery Devices Market Analysis By Drug Delivery Type (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical), By Gene Delivery Vector (Viral, Non-viral), By Gene Delivery Type (In situ, Ex vivo), And Segment Forecasts, 2018 - 2025

  • Published Date: Dec, 2016
  • Base Year for Estimate: 2015
  • Report ID: GVR-1-68038-238-9
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2015
  • Number of Pages: 90

Market segmentation

  • Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
    • Oral
    • Inhalation
    • Transdermal
    • Injectable
    • Ocular
    • Nasal
    • Topical
  • Vector Outlook (Revenue, USD Million, 2014 - 2025)
    • Viral
    • Non-viral
  • Method Outlook (Revenue, USD Million, 2014 - 2025)
    • In situ
    • Ex vivo
  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)
    • North America
      • The U.S.
        • U.S. Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • U.S. Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • U.S. Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
      • Canada
        • Canada Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • Canada Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • Canada Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
    • Europe
      • UK
        • UK Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • UK Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • UK Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
      • Germany
        • Germany Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • Germany Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • Germany Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
    • Asia Pacific
      • Japan
        • Japan Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • Japan Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • Japan Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
      • China
        • China Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • China Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • China Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
    • Latin America
      • Brazil
        • Brazil Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • Brazil Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • Brazil Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
      • Mexico
        • Mexico Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • Mexico Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • Mexico Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo
    • MEA
      • South Africa
        • South Africa Route of Administration Outlook (Revenue, USD Billion, 2014 - 2025)
          • Oral
          • Inhalation
          • Transdermal
          • Injectable
          • Ocular
          • Nasal
          • Topical
        • South Africa Vector Outlook (Revenue, USD Million, 2014 - 2025)
          • Viral
          • Non-viral
        • South Africa Method Outlook (Revenue, USD Million, 2014 - 2025)
          • In situ
          • Ex vivo

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.